Single-center phase 2 trial of first-line olverembatinib plus venetoclax and reduced-intensity chemotherapy for Ph+ acute lymphoblastic leukemia

A phase 2 trial at the Chinese Academy of Medical Sciences & Peking Union Medical College in Tianjin found promising activity and tolerability of the combination of the third-generation BCR-ABL1 tyrosine kinase inhibitor olverembatinib with the BCL-2 inhibitor venetoclax and reduced-intensity chemotherapy for newly diagnosed Ph+ acute lymphoblastic leukemia in adult patients, providing an alternative treatment strategy for patients who are unfit for immunotherapy or intensive chemotherapy at the initial stage of treatment.